Tohobio and Hansen Pharmaceuticals signed a $68 million cooperation agreement on new leukemia drugs.

On July 28, Terns Pharmaceuticals, a global innovation drug company focused on chronic liver disease and cancer, today announced the signing of a product cooperation and licensing agreement with Hansen Pharmaceuticals, Asia's leading research and development-driven pharmaceutical company.
Henson Pharmaceuticals will receive a development and commercialization interest in trna-000632 in Greater China.
trna-000632 is a highly active BCR-ABL protein deflator inhibitor that is being used to develop chronic myeloid leukemia (CML)-related indications.
under the terms of the agreement, Hansen will receive exclusive rights in the development and commercialization of trna-000632 in Greater China (Chinese mainland, Hong Kong, Macau, Taiwan).
will receive a down payment of no more than $68 million, research and development, registration, sales milestone payments, and future sales-based sales-based commissions.
to retain the development and commercialization of its products in other markets around the world.
the emergence of tyrosine kinase inhibitors has benefited many patients with chronic myeloid leukemia, but there are still many patients who have a drug resistance response to this type of drug, unable to achieve the desired therapeutic effect.
trna-000632 can be targeted at the unique structural binding site of the mutated BCR-ABL protein, and there is a significant difference from the tyrosine kinase inhibitor currently targeted at the active binding site of adenosine triphosphate, so it will further improve the therapeutic effect and reduce the patient's drug resistance.
References: The T.C. TsengS bio-signed the TRN-000632 Greater China Exclusive Product Licensing Cooperation Agreement with Johnson Pharmaceuticals. Retrieved 2020-07-28, from.